Clinical experience with leflunomide in rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue SUPPL. 53, 1998, Pages 27-32

  Rozman, Blaž ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Disease modifying antirheumatic drugs; Leflunomide; Rheumatoid arthritis

Indexed keywords

ALBUMIN; COLESTYRAMINE; ESTROGEN; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE;

ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; IMMUNOLOGY; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES;

EID: 0031838192     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
2. van der Heide A, Jacobs JW, Bijlsma JWJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
3. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
4. Pincus T. Long-term outcomes in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:S59-S73.
5. Mulherin D, Fitzgerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. Br J Rheumatol 1996;35:1263-8.
6. Wijnands MJH, van Kiel PLCM. Management of adverse effects of disease-modifying antirheumatic drugs. Drug Safety 1995;13: 219-27.
7. Thoss K, Henzgen S, Petrow PK, Katenkamp D, Brauer R. Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. Inflamm Res 1996;45:103-7.
8. Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski JP. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions 1987;21:241-3.
9. Glnt TT, Mikecz K, Bartlett RR, et al. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacol 1992;3:105-16.
10. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35:1270-3.
11. Mladenovic V, Domljan Z,Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995;38:1595-603.
12. Leflunomide Investigator's Brochure. Weisbaden, Germany: Hoechst AG; March 1995.
13. United States Food and Drug Administration. Summary basis of approval, methotrexate: NDA 8085/S028. Washington, DC: United States Department of Health and Human Services, 1988.
14. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;3:477-84.
15. van der Heide A, Remme CA, Hofman DM, Jacobs JW,Bijlsma JWJ. Prediction of progression of radiologie damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
16. Rozman B, Domljan Z, Popovic M, et al. Long term administration of leflunomide to patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1994;37 Suppl 9:S339.
17. Weber W, Harnisch L. Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD, in the treatment of rheumatoid arthritis. In: Aarons L, Balant LP, Danhof M, et al, editors. European cooperation in the field of scientific and technical research. Brussels: European Commission Directorate-General Science, Research and Development; 1997:239-44.
18. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. New Engl J Med 1985;312:812-22.
19. Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985;28:721-30.
20. Pullar T, Hunter JA, Capell HA. Sulfasalazine in rheumatoid arthritis: a double-blind comparison of sulfasalazine with placebo and sodium aurothiomalate. BMJ 1983;287:1102-4.
21. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983; 26:1303-15.
22. Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporine versus placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051-15.